US EditionAkeso Enrolled First Patient in The Phase III Clinical Trial of Ivonescimab in Combination with Chemotherapy for First-Line Treatment of Triple-Negative Breast Cancer
- Akeso, Inc. Announced the successful enrollment of the first patient in its Phase III clinical trial of ivonescimab with chemotherapy for treating triple-negative breast cancer.
- The trial is led by Professor Xu Binghe from the Cancer Hospital of the Chinese Academy of Medical Sciences.
- Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody developed by Akeso and has shown significant therapeutic efficacy.
- Akeso aims to reshape cancer immunotherapy standards with its robust pipeline of over 50 innovative assets, including ivonescimab.
Insights by Ground AI
Does this summary seem wrong?
47 Articles
47 Articles
All
Left
6
Center
11
Right
2
Coverage Details
Total News Sources47
Leaning Left6Leaning Right2Center11Last UpdatedBias Distribution58% Center
Bias Distribution
- 58% of the sources are Center
58% Center
L 32%
C 58%
11%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
